**Uroplakin II**
Concentrated and Prediluted Monoclonal Antibody
901-3051-042418

---

**Catalog Number:**
- ACI 3051 A, C
- API 3051 AA
- OAI 3051 T60
- AVI 3051 KG

**Description:**
- 0.1, 1.0 ml, concentrated
- 6.0 ml, prediluted
- 60 tests, prediluted
- Ready-to-use
- Ready-to-use
- N/A

**Diluent:**
- Van Gogh Yellow
- N/A

---

**Intended Use:**
For In Vitro Diagnostic Use

Uroplakin II [BC21] is a mouse monoclonal antibody that is intended for laboratory use in the qualitative identification of uroplakin II protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

**Summary and Explanation:**
Uroplakin II is a 15 kDa protein component of urothelial plaques, which enhance the permeability barrier of the urothelium (1). Studies have shown Uroplakin II mRNA was expressed in bladder cancer tissues and peripheral blood of patients with primary and metastatic urothelial carcinoma of the bladder (2,3). A new mouse monoclonal Uroplakin II antibody [BC21] was developed and exhibited an increased staining sensitivity (46/59, 78%) when compared to Uroplakin III [AU1] (19/56, 34%) in cases of urothelial carcinoma of the bladder (see Performance Characteristics). With the exception of bladder and ureter, Uroplakin II [BC21] was found to be highly specific when evaluated in various normal and neoplastic tissues, including prostate cancer and renal cell carcinoma (see Performance Characteristics). Uroplakin II [BC21] is a highly specific antibody that may be useful in identifying tumors of urothelial origin.

**Principle of Procedure:**
Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. A secondary antibody may be applied to bind the primary antibody, followed by an enzyme labeled polymer; or an enzyme labeled polymer may be applied directly to bind the primary antibody. The detection of the bound primary antibody is evidenced by an enzyme-mediated colorimetric reaction.

**Source:**
Mouse monoclonal

**Species Reactivity:**
- Human;
- others not tested

**Clone:**
- BC21

**Isotype:**
- IgG1/kappa

**Total Protein Concentration:**
~10 mg/ml. Call for lot specific Ig concentration.

**Epitope/Antigen:**
- Residues 36-50 of human Uroplakin II

**Cellular Localization:**
- Cytoplasmic and membrane

**Positive Tissue Control:**
- Normal bladder or urothelial carcinoma of the bladder

**Known Applications:**
- Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

**Supplied As:**
Buffer with protein carrier and preservative

For AVI3051KG:
- Uroplakin II (AVI3051G) 1 x 6ml
- V-Blocker (BRI4001G) 1 x 6ml

**Storage and Stability:**
Store at 2°C to 8°C. Do not use after expiration date printed on vial. If reagents are stored under conditions other than those specified in the package insert, they must be verified by the user. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

**Protocol Recommendations (intelliPATH and manual use) Cont’d:**

**Protocol Recommendations (ONCORE Automated Slide Staining System):**
OA13051 is intended for use with the ONCORE Automated Slide Staining System. Refer to the User Manual for specific instructions for use. Protocol parameters in the ONCORE Automated Slide Stainer Protocol Editor should be programmed as follows:

**Protocol Name:**
- Uroplakin II

**Protocol Template (Description):**
- Ms HRP Template 1

**Dewaxing (DS Option):**
- DS2

**Antigen Retrieval (AR Option):**
- AR2, low pH; 101°C

**Reagent Name, Time, Temp.:**
- Uroplakin II; 30 min., 25°C

**Protocol Recommendations (Ventana BenchMark XT / ULTRA Slide Staining Systems):**
AVI3051 is intended for use with the Ventana BenchMark XT / ULTRA Slide Staining Systems. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

- Using ultraView on XT / ULTRA:
  - Template/Detection: ultraView DAB
  - Pretreatment Protocol: CC1 Mild
  - Primary Antibody: 32 minutes, 37°C
  - ultraBlock (V-Blocker BRI4001): Incubate for 4 minutes (with appropriate Option # registered by user) V-Blocker is recommended to be applied prior to any detection system.

- Using OptiView on ULTRA:
  - Template/Detection: OptiView DAB IHC
  - Pretreatment Protocol: CC1 32 minutes
  - Peroxidase: Pre Primary Peroxidase Inhibitor
  - Primary Antibody: 8 minutes, 36°C

**Technical Note:**
This antibody, for intelliPATH and manual use, has been standardized with Biocare's MACH 4 detection system. Use TBS for washing steps.

**Performance Characteristics:**
- Sensitivity, specificity and cross-reactivity were determined by staining with MACH 4 Universal HRP-Polymer Detection. See Tables 1 and 2 for expected results.

**Limitations:**
The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions. The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology and other histopathological criteria by a qualified pathologist. The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology and other histopathological criteria by a qualified pathologist.
Uroplakin II
Concentrated and Prediluted Monoclonal Antibody
901-3051-042418

Limitations Cont’d:
staining should be complemented by morphological studies using proper
positive and negative internal and external controls as well as other
diagnostic tests.

Quality Control:
Refer to CLSI Quality Standards for Design and Implementation of
Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-
A2) CLSI Wayne, PA USA (www.clsi.org). 2011

Precautions:
1. This antibody contains less than 0.1% sodium azide. Concentrations less
than 0.1% are not reportable hazardous materials according to U.S. 29 CFR
1910.1200, OSHA Hazard communication and EC Directive 91/155/EC.
Sodium azide (NaN3) used as a preservative is toxic if ingested. Sodium
azide may react with lead and copper plumbing to form highly explosive
metal azides. Upon disposal, flush with large volumes of water to prevent
azide build-up in plumbing. (Center for Disease Control, 1976, National
Institute of Occupational Safety and Health, 1976) (5)
2. Specimens, before and after fixation, and all materials exposed to them
should be handled as if capable of transmitting infection and disposed of
with proper precautions. Never pipette reagents by mouth and avoid
contacting the skin and mucous membranes with reagents and specimens.
If reagents or specimens come into contact with sensitive areas, wash with
copious amounts of water. (6)
3. Microbial contamination of reagents may result in an increase in
nonspecific staining.
4. Incubation times or temperatures other than those specified may give
erroneous results. The user must validate any such change.
5. Do not use reagent after the expiration date printed on the vi
6. The SDS is available upon request and is located at http://biocare.net.

Troubleshooting:
Follow the antibody specific protocol recommendations according to data
sheet provided. If atypical results occur, contact Biocare’s Technical
Support at 1-800-542-2002.

References:
2. Wu X, et al. Uroplakin II as a promising marker for molecular diagnosis
of nodal metastases from bladder cancer: comparison with cytokeratin 20. J
3. Lu JJ, et al. Detection of circulating cancer cells by reverse transcription-
polymerase chain reaction for uroplakin II in peripheral blood of patients
with transitional cell carcinoma of the bladder. J Urol. 1999 Sep; 162(3 Pt
1):931-95.
CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink
Drains to Remove Azide Salts.”
6. Clinical and Laboratory Standards Institute (CLSI). Protection of
Laboratory Workers from Occupationally Acquired Infections; Approved

VP Echelon Series antibodies are developed solely by Biocare Medical LLC
and do not imply approval or endorsement of Biocare’s antibodies by
Ventana Medical Systems, Inc. Biocare and Ventana are not affiliated,
associated or related in any way. Ventana®, BenchMark®, ultraView and
OptiView are trademarks of Roche.

Table 1: Sensitivity and specificity were determined by testing formalin-
fixed, paraffin-embedded neoplastic tissues.

<table>
<thead>
<tr>
<th></th>
<th># Positive / Total Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder cancer</td>
<td>46/59*</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>1/88**</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>0/20</td>
</tr>
<tr>
<td>Kidney cancer (various phenotypes)</td>
<td>3/75***</td>
</tr>
<tr>
<td>Colon cancer</td>
<td>0/63</td>
</tr>
<tr>
<td>Brain cancer</td>
<td>0/13</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>0/25</td>
</tr>
<tr>
<td>Melanoma</td>
<td>0/19</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>0/11</td>
</tr>
<tr>
<td>Seminoma</td>
<td>0/14</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>0/74</td>
</tr>
<tr>
<td>Adrenal gland cancer</td>
<td>0/2</td>
</tr>
<tr>
<td>Thyroid cancer</td>
<td>0/2</td>
</tr>
<tr>
<td>Pancreas cancer (various phenotypes)</td>
<td>0/10</td>
</tr>
<tr>
<td>Head &amp; neck cancer (various phenotypes)</td>
<td>0/10</td>
</tr>
<tr>
<td>Soft tissue cancer (various phenotypes)</td>
<td>0/10</td>
</tr>
<tr>
<td>Liver cancer (various phenotype)</td>
<td>0/10</td>
</tr>
<tr>
<td>Cervix cancer (various phenotypes)</td>
<td>0/10</td>
</tr>
</tbody>
</table>

* For comparison, Uroplakin III [Clone AU1] stained 19/56 cases of bladder
cancer.
** 1 positive case, which may be metastatic bladder cancer that has spread to
prostate.
*** 3 positive cases, which are transitional cell carcinomas from upper ureters

Table 2: Tissue cross-reactivity was determined by testing formalin-fixed,
paraffin-embedded normal tissues.

<table>
<thead>
<tr>
<th>Tissue</th>
<th># Positive / Total Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenal gland</td>
<td>0/3</td>
</tr>
<tr>
<td>Bladder</td>
<td>5/7</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>0/1</td>
</tr>
<tr>
<td>Eye</td>
<td>0/2</td>
</tr>
<tr>
<td>Breast</td>
<td>0/3</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>0/3</td>
</tr>
<tr>
<td>Cerebral cortex</td>
<td>0/3</td>
</tr>
<tr>
<td>Fallopian tube</td>
<td>0/3</td>
</tr>
<tr>
<td>GI-Esophagus</td>
<td>0/3</td>
</tr>
<tr>
<td>GI-Stomach</td>
<td>0/3</td>
</tr>
<tr>
<td>GI-Small intestine</td>
<td>0/3</td>
</tr>
<tr>
<td>GI-Colon</td>
<td>0/3</td>
</tr>
<tr>
<td>GI-Rectum</td>
<td>0/3</td>
</tr>
<tr>
<td>Heart</td>
<td>0/3</td>
</tr>
<tr>
<td>Kidney</td>
<td>0/16</td>
</tr>
<tr>
<td>Liver</td>
<td>0/5</td>
</tr>
<tr>
<td>Lung</td>
<td>0/3</td>
</tr>
<tr>
<td>Ovary</td>
<td>0/3</td>
</tr>
<tr>
<td>Blood vessel and</td>
<td>0/1</td>
</tr>
<tr>
<td>adipose tissue</td>
<td></td>
</tr>
</tbody>
</table>

Lineage of Biocare’s antibodies by

Troubleshooting: